A case of a long-term survival achieved by surgical treatment and chemotherapy for late recurrence of AFP-producing gastric cancer

Manabu Harada, Hironori Tsujimoto*, Takashi Ichikura, Hiromi Nagata, Nozomi Ito, Shinsuke Nomura, Hiroyuki Horiguchi, Yoshihisa Yaguchi, Yoji Kishi and Hideki Ueno

Abstract

Background: Alpha-fetoprotein-producing gastric cancer (AFP-GC) is a relatively rare disease, with a dismal prognosis.

Case presentation: We report the case of a patient with long-term survival after surgery for the recurrence of AFP-GC. A 71-year-old man was diagnosed with gastric cancer and underwent distal gastrectomy with D2 lymphadenectomy (pT3N2M0). Pathological examination of the resected specimen revealed AFP-GC. Fifteen years after the gastrectomy, the patient experienced anorexia and was admitted with a mass located at the mesentery of the small intestine. Following a diagnosis of gastrointestinal stromal tumor of the mesentery, a tumor resection with partial small intestine was performed. The final histopathological diagnosis was AFP-GC’s recurrence in the small-bowel mesentry. Two months later, multiple liver metastases were identified, and serum AFP level was found to be extremely high (17,447 ng/mL). Chemotherapy with S-1+CDDP (SP) was initiated for liver metastasis. However, owing to anorexia and fatigue, SP therapy was discontinued following the patient’s request at the end of two courses. A CT scan at 1 month after the discontinuation of chemotherapy did not reveal liver metastasis, and serum AFP level decreased to the normal range. He is alive at present with no recurrence and no elevation of serum AFP level at 7 years after the second surgery without any chemotherapy.

Conclusion: Even if recurrence of AFP-GC is diagnosed, radical resection and chemotherapy are effective, as noted in the present case.

Keywords: Alpha-fetoprotein, Gastric cancer, Recurrence, Long-term survival

Background

Alpha-fetoprotein-producing gastric cancer (AFP-GC) is a relatively rare disease, accounting for 1.3–15% cases of gastric cancer [1, 2]. AFP-GC is associated with poor prognosis because of high rates of liver and lymph node metastases [3, 4]. Synchronous or metachronous liver metastases have been frequently observed in AFP-GC, even in the early stage of cancer [1]. Earlier studies have reported that significant prognostic factors in AFP-GC were liver metastasis and pathological stage [5, 6].

Herein, we present a case of a patient with long-term survival after successful treatment with radical surgery for the solitary metastasis of the mesentery and chemotherapy for the multiple liver metastases of AFP-GC at 22 years after the first gastrectomy.

Case presentation

A 71-year-old man was admitted to our hospital with complaints of persistent anorexia. Fifteen years ago, he had undergone distal gastrectomy with D2 lymphadenectomy, followed by Billroth-II type reconstruction for gastric cancer. Pathological examination of the gastric tumor revealed an AFP-GC, and the pathological stage
was pT3 (SS) N2 M0, stage IIB (Japanese classification of
gastric carcinoma: 3rd English edition) [7]. The serum
AFP level was 3720 ng/mL (normal range < 10 ng/mL)
preoperatively and decreased to 8.0 ng/mL after gastrec-
tomy performed 15 years ago. With the exceptions of the
hemoglobin (7.8 g/dL) and serum AFP (17,447 ng/mL)
levels, all serum levels tested were within the normal
range. Hepatitis B and C were negative, and he did not
have any elevated aminotransferases. The levels of carci-
noembryonic antigen (normal range < 5.3 ng/mL) and
carbohydrate antigen 19-9 (normal range < 37 U/mL)
were 4.1 ng/mL and 13.5 U/mL, respectively. Upper
gastrointestinal series revealed a contrast medium in the
ulcerative lesion from the afferent jejunum (Fig. 1a).
Endoscopic examination demonstrated the presence of
an ulcerative lesion located at 15 cm from the site of
anastomosis of gastrojejunostomy at the afferent je-
junum. Pathological examination of biopsy specimens
revealed adenocarcinoma consistent with primary gastric
cancer resected 15 years ago. An abdominal contrast-
enhanced computed tomography (CE-CT) revealed the
presence of a 70-mm-sized mass at the mesentery of the
jejunum (Fig. 1b). Fluorodeoxyglucose positron emission
tomography (FDG-PET) demonstrated the presence of
an abnormal accumulation of FDG at the mass without
any distant metastasis. Based on these findings, we sus-
pected a metastatic tumor from gastric cancer at the
mesentery of the jejunum and performed a laparotomy.
Macroscopically, a 75 × 70-mm-sized mass, infiltrating
all the layers of jejunum wall, was found at the mesen-
tery of the jejunum (Fig. 1c), and partial resection of the
jejunum was then performed. Pathological examination
revealed tumor cells with an acidophilic cells with an al-
veolar growth pattern (Fig. 2). Such observations were
comparable with the primary gastric cancer’s patho-
logical features. Immunohistochemical examination indi-
cated that the tumor cells were positive for AFP and
cytokeratin 18 and negative for cytokeratin 7 and 20.
Consequently, we diagnosed the tumor to have metaста-
sized from the AFP-GC resected 15 years previously.
The preoperative serum AFP levels, which were postop-
eratively examined, were 17,447 ng/mL (normal range <
10 ng/mL). The patient was uneventfully discharged on
the 15th postoperative day.
Two months after the second surgery, CE-CT scan re-
vealed multiple liver metastases (Fig. 3) and serum AFP
level increased to 94,838 ng/mL (Fig. 4). Therefore,
chemotherapy with S-1+CDDP was initiated. However,
after two courses of therapy, the patient refused any fur-
ther treatment owing to severe adverse effects (i.e., appe-
tite loss and general fatigue). A CE-CT scan performed
after two courses of chemotherapy revealed that all liver
metastatic lesions disappeared. Additionally, serum AFP
levels declined to normal range (1.0 ng/mL). Seven years
after the second surgery, and without any chemotherapy,
the patient is alive and well, without any recurrence.

Discussion
Previous studies have reported a poor prognosis for
AFP-GC with lymphatic and venous invasion, along with
high rates of liver metastasis as compared with non-
AFP-GC [4, 8, 9]. In a study by Liu et al., the authors re-
ported that the 1-, 3-, and 5-year survival rates of AFP-
GC were 53%, 35%, and 28%, respectively [6]. However,
Kripp et al. described a long-term survival case of unre-
sectable AFP-GC of the esophago-gastric junction with
several liver metastases, which was successfully treated
with capecitabine- and oxaliplatin-based combination
therapy [10]. Of note, Shibata et al. also reported the
case of a patient who underwent both distal gastrectomy
for early AFP-GC and left hepatectomy 20 months later.
The patient survived without any recurrence for over 11
years after the first diagnosis [11]. Thus, recently, there
has been an increase in the number of reports on AFP-
GC patients with long-term survival because of multi-
modal treatments [6, 12, 13].
Our case highlights three key learning points: first, the long-term (i.e., 15 years) dormancy following the initial gastrectomy until the identification of the solitary metastasis to the mesentery; second, the multiple liver metastases, which went unobserved for 15 years, were evident only 2 months after the second surgery; and last, the disappearance of liver metastases for 5 years following only two courses of chemotherapy with S-1+CDDP.

Gastric cancer usually recurs within the first 2 years of gastrectomy. Late recurrences are rare, with approximately < 1% cases recurring after 10 years [14]. Prognostic factors for early recurrence, such as clinical stage, tumor size, depth of invasion, and lymph node involvement, are not useful in predicting late cancer recurrence [15]. The phenomenon of late recurrence has been partially explained by tumor dormancy. Specifically, it has been shown that dormancy can be present in the form of an early stage in tumor development, as a micrometastasis, or as minimal residual disease post-surgical removal or treatment of the primary tumor [16–18]. In gastric cancer, minimal residual disease was revealed in the blood, bone marrow, negative lymph nodes, and peritoneal cavity [19]. Till date, transition mechanism from dormancy to recurrence has not been completely

Fig. 2 Microscopic findings. Pathological examination indicated that the tumor cells had selling nucleus and acidophilic cells with alveolar growth pattern. Additionally, immunohistochemical examination indicated AFP positivity of the tumor cells, similar to the pathological features of primary gastric cancer resected 15 years ago.

Fig. 3 CT scan images before and after chemotherapy. Abdominal contrast-enhanced computed tomography revealed multiple low-density areas (arrows) 2 months after the second surgery. After 2 courses of chemotherapy, a CT scan revealed absence of all liver metastatic lesions.
explained, particularly in gastric cancer. Although precise mechanisms remain to be elucidated, increasing evidence suggest that many cancer patients suffer from metastatic relapse several years after they have undergone radical surgery [18]. Thus, the second surgery reactivated the tumor cells which were dormant for 15 years. Additional studies aimed at better understanding of tumor dormancy are necessary to predict late recurrence and to strengthen the follow-up protocol for long-term survivors of gastric cancer.

In an earlier study, Adachi et al. analyzed 270 AFP-GC cases. The authors reported that the 5-year survival rate and median survival period in all patients were 22% and 14 months, respectively. However, they found that patients with curative gastrectomy comprised 42% of the study cohort and median survival period was 29 months [5]. Of note, Inoue et al. analyzed 53 AFP-GC cases reporting a 5-year survival rate of 34% (18/53) [20]. Our patient was alive 15 years after a curative distal gastrectomy, until the recurrence of mesentery of jejunum.

In Japan, SP therapy for unresectable and recurrent gastric cancers has been recognized as the standard therapy [21]. At the time of diagnosis, our patient was expected to have a poor prognosis due to recurrence of AFP-GC. However, only two courses of chemotherapy with SP were extremely effective on metachronous liver metastases. Surprisingly, the patient is alive without any sign of recurrence at 7 years after the second surgery. With the development of chemotherapy strategies, there are increasing cases who achieved complete response by only several courses of chemotherapy in unresectable gastric cancer [22, 23]. Further accumulation of cases is required for selecting such patients.

**Conclusion**

Even if recurrence of AFP-GC is diagnosed, there are cases in which radical resection and chemotherapy are effective, as noted in the present case. Additional accumulation of AFP-GC cases is necessary to identify and select such cases.

**Abbreviations**

AFP-GC: Alpha-fetoprotein-producing gastric cancer; SP: Chemotherapy with S-1+CDDP

**Acknowledgements**

The authors thank Enago (www.enago.jp) for the English language review.

**Authors’ contributions**

MH, HT, YK, and HU wrote the paper. All authors read and approved the final manuscript.

**Funding**

None.

**Availability of data and materials**

All data are available on request.

**Ethics approval and consent to participate**

The study protocol was approved by the Institutional Review Board of National Defense Medical College Hospital.

**Consent for publication**

A written informed consent was obtained from all patients prior to the initiation of this study.

**Competing interests**

The authors declare that they have no competing interests.

**Received:** 31 May 2019 **Accepted:** 21 June 2019

**Published online:** 01 July 2019

**References**

1. Chang YC, Nagasue N, Kohno H, Taniura H, Uchida M, Yamanoi A, et al. Clinicopathologic features and long-term results of alpha-fetoprotein-producing gastric cancer. Am J Gastroenterol. 1990;85(11):1480–5.
2. McIntire KR, Waldmann TA, Moertel CG, Go VL. Serum alpha-fetoprotein in patients with neoplasms of the gastrointestinal tract. Cancer Res. 1975;35(4):991–6.

3. Chang YC, Nagasue N, Abe S, Taniura H, Kumar DD, Nakamura T. Comparison between the clinicopathologic features of AFP-positive and AFP-negative gastric cancers. Am J Gastroenterol. 1992;87(3):321–5.

4. Kono K, Amemiya H, Sekikawa T, Izuka H, Takahashi A, Fuji H, et al. Clinicopathologic features of gastric cancers producing alpha-fetoprotein. Dig Surg. 2002;19(5):359–65 discussion 65.

5. Adachi Y, Tsuchihashi J, Shiraishi N, Yasuda K, Etch T, Kitano S. AFP-producing gastric carcinoma: multivariate analysis of prognostic factors in 270 patients. Oncology. 2003;65(2):95–101.

6. Liu X, Cheng Y, Sheng W, Lu H, Xu Y, Long Z, et al. Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers: analysis of 104 cases. J Surg Oncol. 2010;102(3):249–55.

7. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101–12.

8. Ishigami S, Natsugoe S, Nakashima H, Tokuda K, Nakajo A, Okumura H, et al. Biological aggressiveness of alpha-fetoprotein (AFP)-positive gastric cancer. Hepatogastroenterology. 2006;53(69):338–41.

9. Lee R, Rha SY, Ahn JB, Shim KY, Choi JH, Lim HY, et al. Alpha-fetoprotein-producing gastric cancer. Oncol Rep. 1998;5(5):1179–84.

10. Kripp M, Strobel P, Dinter D, Lukas N, Hochhaus A, Hofheinz RD. Alpha-fetoprotein expressing metastatic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaplatin. Anti-Cancer Drugs. 2009;20(1):75–8.

11. Shibata Y, Sato K, Kodama M, Nanjyo H. Alpha-fetoprotein-producing early gastric cancer of the remnant stomach: report of a case. Surg Today. 2007;37(1):995–9.

12. Fang YU, Wang L, Yang N, Gong X, Zhang YU, Qin S. Successful multimodal therapy for an alpha-fetoprotein-producing gastric cancer patient with simultaneous liver metastases. Oncol Lett. 2015;10(5):3201–5.

13. Nakao S, Nakata B, Tendo M, Kuroda K, Hori T, Inaba M, et al. Salvage surgery after chemotherapy with 5-FU plus cisplatin for alpha-fetoprotein-producing gastric cancer with a portal vein tumor thrombus: a case report. BMC Surg. 2015;15:55.

14. Moon YW, Jeung HC, Rha SY, Yoo NC, Roh JK, Noh SH, et al. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single Korean institute. Ann Surg Oncol. 2007;14(10):2730–7.

15. Lee JH, Kim HI, Kim MG, Ha TK, Jung MS, Kwon SJ. Recurrence of gastric cancer in patients who are disease-free for more than 5 years after primary resection. Surgery. 2016;159(4):1090–8.

16. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7(11):834–46.

17. Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell. 2013;23(5):573–81.

18. Giancotti FG. Mechanisms governing metastatic dormancy and reactivation. Cell. 2013;155(4):750–64.

19. Shin JH, Chung J, Kim HO, Kim YH, Hur YM, Rhim JH, et al. Detection of cancer cells in peripheral blood of stomach cancer patients using RT-PCR amplification of tumour-specific mRNAs. Aliment Pharmacol Ther. 2002;16(Suppl 2):137–44.

20. Inoue M, Sano T, Kuchiba A, Taniguchi H, Fukagawa T, Katali H. Long-term results of gastrectomy for alpha-fetoprotein-producing gastric cancer. Br J Surg. 2010;97(7):656–61.

21. Aoyama T, Yoshikawa T, Watanabe T, Hayashi T, Ogata T, Cho H, et al. Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1. Gastric Cancer. 2011;14(2):150–4.

22. Yan ZJ, Wang JX, Liu YY, Li ZH, Zhang LJ, Gui P, et al. A case of complete remission from advanced gastric adenocarcinoma with synchronous liver metastasis in response to EOX chemotherapy. Case Rep Gastrointest Med. 2018;2018:3954260.

23. Tada K, Etch T, Shtomi Y, Ueda Y, Tojigamori M, Shirouma H, et al. A case of advanced gastric cancer achieved a pathological complete response by chemotherapy. Surg Case Rep. 2017;3(1):68.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.